Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04665830 | PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients | PHASE3 | COMPLETED | 200 | — | — | May 1, 2018 | May 1, 2020 | Dec 14, 2020 | 1 | Kuwait |
cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization
| Arm | Type | Description |
|---|---|---|
| Group 1 | ACTIVE_COMPARATOR | Evolocumab group, patients who are receiving this therapy for 12 months. |
| Group 2 | PLACEBO_COMPARATOR | The Statin group includes patients who are maintained on statin therapy. |
| Name | Type | Description |
|---|---|---|
| Evolocumab | DRUG | treated patients with evolocumab for high cholesterol |
Inclusion Criteria: * 1\. Signed informed consent, 2. Male or female Kuwaiti older than 30 and younger than ≤ 80 years of age at the signing of informed consent 3. History of clinically evident cardiovascular disease(diagnosis of myocardial infarction; non-hemorrhagic stroke or symptomatic peripher...